Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study

Ann N Y Acad Sci. 1990:616:346-55. doi: 10.1111/j.1749-6632.1990.tb17855.x.

Authors

M A Wainberg¹, M Tremblay, R Rooke, N Blain, H Soudeyns, M A Parniak, X J Yao, X G Li, M Fanning, J S Montaner, et al.

Affiliation

¹ Jewish General Hospital, Montreal, Canada.

PMID: 1706573
DOI: 10.1111/j.1749-6632.1990.tb17855.x

No abstract available

Publication types

Clinical Trial
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Acquired Immunodeficiency Syndrome / drug therapy*
Acquired Immunodeficiency Syndrome / epidemiology
Canada / epidemiology
Cells, Cultured
Drug Resistance, Microbial / genetics
Genetic Variation
HIV-1 / drug effects*
HIV-1 / enzymology
HIV-1 / genetics
HIV-1 / isolation & purification
Humans
Kinetics
Leukocytes, Mononuclear / drug effects
Leukocytes, Mononuclear / microbiology
Membrane Glycoproteins / metabolism
Nucleosides / pharmacology*
Nucleosides / therapeutic use
RNA-Directed DNA Polymerase / metabolism*
Sensitivity and Specificity
Viral Envelope Proteins / metabolism
Zidovudine / pharmacology*
Zidovudine / therapeutic use

Substances

Membrane Glycoproteins
Nucleosides
Viral Envelope Proteins
Zidovudine
RNA-Directed DNA Polymerase